ACM
IART icon

Aster Capital Management’s Integra LifeSciences IART Stock Holding History

Aster Capital Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,797
Closed -$22K – 1148
2025
Q2 		$22K Buy
+1,797
New +$26.1K 0.01% 695
2024
Q4 		– Sell
-605
Closed -$11K – 1293
2024
Q3 		$11K Buy
+605
New +$14K ﹤0.01% 786

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aster Capital Management's IART Position: Q3 2025 in Review

Aster Capital Management sold out of Integra LifeSciences (IART) in Q3 2025, closing a stake of 1,797 shares — an estimated $22K sold.

Aster Capital Management first reported a position in IART in Q3 2024 and held it in 2 quarters. The position peaked at $22K in Q2 2025. 207 funds tracked by Wall St. Rank hold IART as of Q3 2025.

  • Aster Capital Management reported no remaining Integra LifeSciences position as of Q3 2025 after selling out during the quarter.
  • Aster Capital Management sold 1,797 Integra LifeSciences shares in Q3 2025, an estimated $22K.
  • Aster Capital Management first reported a position in Integra LifeSciences in Q3 2024 and held it in 2 quarters.
  • Aster Capital Management's Integra LifeSciences position peaked at $22K in Q2 2025.
  • 207 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2025.

Based on Aster Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.